DeLyle W. Bloomquist - 16 Jun 2021 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

Role
Resigned as a Director on June 17, 2021.
Signature
/s/ Hillary Yegen, attorney-in-fact
Issuer symbol
PDSB
Transactions as of
16 Jun 2021
Net transactions value
+$116,568
Form type
4
Filing time
21 Jun 2021, 16:30:48 UTC
Previous filing
20 May 2021
Next filing
19 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PDSB Common Stock Options Exercise $17,790 +2,970 +1.6% $5.99 183,888 16 Jun 2021 Direct F1
transaction PDSB Common Stock Purchase $98,778 +10,000 +5.4% $9.88 193,888 16 Jun 2021 Direct F1, F2
holding PDSB Common Stock 605,023 16 Jun 2021 See Footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PDSB Stock Option (Right to Buy) Options Exercise $0 -2,970 -33% $0.000000 6,030 16 Jun 2021 Common Stock 2,970 $5.99 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

DeLyle W. Bloomquist is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The shares reported on this Form 4 are subject to a lock-up agreement between Mr. Bloomquist and Cantor Fitzgerald & Co. in connection with a public offering of common shares by the Issuer which closed on June 17, 2021.
F2 Represents shares of Common Stock of the Issuer that Mr. Bloomquist purchased in the open market. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.85 to $9.90, inclusive.
F3 Mr. Bloomquist owns 80% of and is the manager of Asklepios Capital LLC and has voting and dispositive power with respect to these shares.
F4 One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 28, 2022, subject in all respects to the option agreement governing the stock option grant.

Remarks:

Resigned as a Director on June 17, 2021.